Minimal change nephrotic syndrome. Histopathology and steroid-responsiveness

Children with minimal change nephrotic syndrome (MCNS) generally respond promptly to initial steroid therapy, undergo a complete remission, and have a good prognosis. MCNS needs to be separated therefore, from other forms of the nephrotic syndrome in which children fail to respond promptly. Investigations carried out by the International Study of Kidney Disease in Children (ISKDC) have confirmed the generally held belief that nephrotic children who respond during an 8-week course of intensive corticosteroid therapy are likely to have MCNS.1 That likelihood is of the order of 90%. Children who do not respond, particularly those aged 6 years or older, are likely to have other glomerular diseases, but renal biopsy in non-responders (continued proteinuria after 8 weeks of treatment) shows that about one-quarter of all non-responders and half of those younger than 6 years none the less have MCNS.3

It has been essential therefore, to identify the histopathological criteria of 'minimal change' and to recognise the limits of histopathological variability. Minor variability within the histopathological category of MCNS was recognised by the ISKDC at the outset,2 and a recent report5 contains an analysis of clinical characteristics and responses to treatment in children having histopathological subcategories of MCNS. Such subcategories include nil disease, focal glomerular obsolescence, mild mesangial thickening, mild mesangial hypercellularity, and focal tubular changes. The criteria allow MCNS to be separated from both focal segmental glomerular sclerosis and more severe degrees of mesangial proliferation. A category of diffuse mesangial hypercellularity has been recognised as intermediate between mild mesangial hypercellularity and diffuse proliferative glomerulonephritis. These definitions and criteria have recently been defined even more rigorously and incorporated into the World Health Organisation’s classification of glomerular diseases.4

The ISKDC study of clinical characteristics at onset showed no important differences among the histopathological subcategories of MCNS,5 except that young patients tended to have glomerular obsolescence, a phenomenon well known to paediatric pathologists. However, more children having mild mesangial hypercellularity and focal tubular changes than those having nil disease, focal glomerular obsolescence, or mild mesangial thickening failed to respond promptly to corticosteroid therapy. Children with diffuse mesangial hypercellularity, that is with a degree of mesangial hypercellularity exceeding the limit set for MCNS, also had a significantly poorer rate of steroid responsiveness than did children with MCNS.

The differences at 8 weeks disappeared however, during 52 weeks of continued corticosteroid therapy. In other words, children with mild mesangial hypercellularity, focal tubular changes, and diffuse mesangial hypercellularity experienced delayed remissions, perhaps resulting from, perhaps abetted by, the prolonged treatment. The ultimately good responsiveness in all categories of MCNS and in diffuse mesangial hypercellularity and the paucity of differentiating clinical characteristics suggests that the differences in histology reflect different severities of glomerular injury rather than different disease processes. Perhaps mild mesangial hypercellularity reflects a more severe degree of glomerular injury than does nil disease and diffuse mesangial hypercellularity is a more severe injury than mild mesangial hypercellularity. On those grounds alone, the response to therapy might be slower or poorer, and recognising different degrees of hypercellularity might resolve the discrepancies reported in responsiveness of nephrotic children with mesangial proliferative abnormalities.1-9 The significance of focal tubular changes is unknown.

The ISKDC analysis of late responses to steroid therapy in patients with different subcategories of MCNS and with diffuse mesangial hypercellularity showed no significant differences.8 There were no differences among the rates of early relapse (relapse during the first 8 weeks of treatment), frequent relapse (2 or more relapses within 6 months of the initial response), late non-response (failure to respond to steroid therapy after having responded previously), and death. Those observations, particularly those relating to late non-response, can be interpreted to mean that relapses are not necessarily of the same severity as the initial episode. We would predict, if relapses were unequal in the severity of glomerular damage, that late non-responsiveness
would be distributed randomly among the different histopathological categories, which is precisely what the data show. Furthermore, the frequency of relapses in individual patients was inconstant and lacked correlation with the histopathological findings.10

The ISKDC data have bearing therefore, on our interpretation of the natural history of the idiopathic nephrotic syndrome in childhood. An initially severe lesion might well be associated with non-responsiveness or with delayed responsiveness to corticosteroid therapy and might carry a high risk of glomerular scarring.11 It would be wrong however, to assume that late non-responsiveness or the late development of focal segmental glomerular sclerosis after an interval of several years necessarily relates to the severity of the initial glomerular disease. Relapses may continue to follow the same pattern of response after the first attack, as they do in the majority of patients, but there is no requirement that they do so. Relapses in that view are not smouldering embers, left over from the initial conflagration, but new outbursts, presumably triggered by identical or similar mechanisms.

Unanswered is the question of steroid-dependence in relation to glomerular histopathology. If steroid-dependent patients include a fairly high proportion with mesangial hypercellularity and glomerular sclerosis,12 steroid-dependence would seem to relate to the severity of glomerular disease. An alternative view however, has been expressed by Arant et al.,13 who suggested that steroid-dependence is related to functional adrenal insufficiency as the result of steroid-induced adrenal suppression. It is also conceivable that some of the glomerular alterations in patients receiving long-term corticosteroid therapy are related to the treatment rather than to the disease, as experimental studies have shown retention of macromolecules in cortisone-treated animals.14 These altered mesangial kinetics might explain the mesangial accumulation of IgM in some patients5 15 and the fairly frequent electron microscopical demonstration of electron-dense ‘deposits’ in children with longstanding MCNS.16

It appears that early response to steroid therapy in the idiopathic nephrotic syndrome predicts the subsequent course with an accuracy of about 85%. The development of late non-response in 15% however, injects a small element of doubt into the physician’s prognostication. Such patients might be candidates for treatment with immunosuppressant drugs, and a large number of them will do well in the long run. A small number of patients may however, develop progressive renal insufficiency as the result of renewed attacks of glomerular injury.

References

JAY BERNSTEIN, JR
Department of Anatomic Pathology, William Beaumont Hospital, Royal Oak, Michigan 48072, USA
CHESTER M EDELMANN, JR
Albert Einstein College of Medicine, Bronx, NY 10461, USA
Minimal change nephrotic syndrome. Histopathology and steroid-responsiveness.

J Bernstein, Jr and C M Edelmann, Jr

Arch Dis Child 1982 57: 816-817
doi: 10.1136/adc.57.11.816

Updated information and services can be found at:
http://adc.bmj.com/content/57/11/816.citation

Email alerting service

These include:

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/